Class 4 Caution in Use on Rifadin (Rifampicin) 150mg Capsules

Recalls and Alerts

Class 4 Caution in Use

Class 4 Caution in Use on Rifadin (Rifampicin) 150mg Capsules

Aventis Pharma Limited t/a Sanofi has informed the MHRA that a change to the Patient Information Leaflet concerning possible side effects for Rifadin (rifampicin) 150mg Capsules has not been implemented by the required timeline.

Please visit the: MHRA website for more details on this drug alert.

The affected products' details are as follows:

PIP Code	Product Description	Supplier	Affected Batch
240838	RIFADIN CAP 150MG	SANOFI	9G020A

For medical information enquiries, please contact Sanofi Medical Information, Tel +44 (0) 845 372 7101; email uk-medicalinformation@sanofi.com.

Recipients of this Drug Alert should bring it to the attention of relevant contacts.

Please note that this is a caution in use only and we are not accepting stock returns.

If you have any questions, then please contact your local Service Centre Customer Services team.